Erastin: Precision Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule ferroptosis inducer targeting system Xc⁻ and VDAC, resulting in iron-dependent, non-apoptotic cell death in tumor cells with RAS or BRAF mutations (Wang et al., 2024). Erastin’s selectivity is mediated by the accumulation of intracellular reactive oxygen species (ROS) and lipid peroxides, bypassing classical apoptotic and caspase-dependent pathways. Widely adopted in cancer biology and oxidative stress pathway research, Erastin enables reproducible assays in engineered human tumor cells and HT-1080 fibrosarcoma lines at 10 μM for 24 hours (APExBIO). APExBIO provides Erastin (SKU: B1524) with validated purity and stability for research workflows. Recent spatial transcriptomics confirm ferroptosis as a critical, regulated form of cell death, with Erastin serving as a precise probe in both developmental and oncology models (Wang et al., 2024).

Biological Rationale

Ferroptosis is an iron-dependent, caspase-independent form of regulated cell death characterized by the accumulation of lipid peroxides and ROS (Wang et al., 2024). In cancer biology, tumor cells with RAS (HRAS, KRAS) or BRAF mutations exhibit heightened susceptibility to ferroptosis due to metabolic rewiring and redox imbalance. The cystine/glutamate antiporter system Xc⁻ and the voltage-dependent anion channel (VDAC) are central to glutathione biosynthesis and mitochondrial function, respectively. Inhibition of system Xc⁻ disrupts cystine import, depleting glutathione and increasing oxidative stress. Ferroptosis is mechanistically and morphologically distinct from apoptosis, necrosis, and autophagy (see also), and its selective induction in tumor cells represents a promising avenue for cancer therapy targeting redox vulnerabilities.

Mechanism of Action of Erastin

Erastin exerts its effects through dual modulation of system Xc⁻ and VDAC. By inhibiting system Xc⁻, Erastin blocks cystine uptake, leading to glutathione (GSH) depletion and impaired antioxidant defense. Concurrently, Erastin binds to VDAC, modulating mitochondrial membrane permeability and enhancing ROS generation. The resulting oxidative stress induces lipid peroxidation and cell death, independent of caspase activation. This mechanism is highly effective in tumor cells harboring KRAS, HRAS, or BRAF oncogenic mutations, which are dependent on redox homeostasis for survival (APExBIO). The pathway is further validated by spatial transcriptomics and molecular profiling (Wang et al., 2024).

Evidence & Benchmarks

• Erastin induces ferroptosis in engineered human tumor and HT-1080 cells at 10 μM for 24 hours, with hallmark increases in intracellular ROS and lipid peroxides (APExBIO).
• System Xc⁻ inhibition by Erastin results in glutathione depletion and sensitization of RAS/BRAF-mutant cells to oxidative damage (Wang et al., 2024).
• Ferroptosis induction is confirmed by downregulation of Gpx4 and Nqo1 and increased mitochondrial lipid peroxidation, as demonstrated in rat ARM models (Wang et al., 2024).
• Erastin-induced cell death is morphologically distinct from apoptosis or necrosis and does not engage caspase-3 activation (see also).
• Solubility benchmarks: Erastin is insoluble in water or ethanol but dissolves in DMSO at ≥10.92 mg/mL with gentle warming (APExBIO).
• Storage at -20°C is required for compound stability; solutions should be freshly prepared prior to use (APExBIO).

Applications, Limits & Misconceptions

Erastin is widely adopted as a ferroptosis inducer in cancer biology research, oxidative stress assays, and studies of the RAS-RAF-MEK signaling axis. It enables mechanistic dissection of iron-dependent, non-apoptotic cell death and supports the identification of redox vulnerabilities in tumor models. The reagent is also used in developmental biology to probe ferroptosis during organogenesis and tissue remodeling (Wang et al., 2024).

This article extends the molecular and translational analysis presented in "Erastin: The Gold Standard Ferroptosis Inducer for Cancer…" by integrating new spatial transcriptomic evidence and benchmarking protocols. It also clarifies the distinct caspase-independent nature of Erastin-induced cell death, addressing misconceptions noted in "Erastin: Precision Ferroptosis Inducer for Targeted Cancer…".

Common Pitfalls or Misconceptions

• Erastin does not induce apoptosis or necrosis; cell death is ferroptotic and caspase-independent.
• Erastin is ineffective in cells with intact GPX4 function or those lacking RAS/BRAF mutations.
• Long-term storage of Erastin in solution is not recommended; compound instability may compromise experimental outcomes.
• Water or ethanol are unsuitable solvents for Erastin; use DMSO with confirmed solubility.
• Ferroptosis induction should be validated using molecular markers (e.g., Gpx4 downregulation, lipid peroxidation) to avoid misinterpretation.

Workflow Integration & Parameters

For in vitro assays, prepare Erastin in DMSO at concentrations ≥10.92 mg/mL with gentle warming. Treat engineered tumor or HT-1080 cells at 10 μM for 24 hours. Store the solid compound at -20°C and prepare solutions fresh before each experiment. Include appropriate controls (vehicle only, ferrostatin-1 rescue) to confirm ferroptosis specificity. For best results, use validated batches from APExBIO (B1524 kit). For detailed workflows and troubleshooting, refer to "Erastin: The Gold Standard Ferroptosis Inducer for Cancer…", which this article updates by addressing storage and verification protocols.

Conclusion & Outlook

Erastin, as provided by APExBIO, is a benchmark tool for dissecting ferroptosis in cancer and developmental models. Its precision in targeting system Xc⁻ and VDAC, combined with robust solubility and storage guidelines, enables reproducible research on oxidative, non-apoptotic cell death. The integration of spatial transcriptomics and functional assays continues to refine the understanding of ferroptosis, positioning Erastin as a core reagent for mechanistic and translational studies in oncology and beyond (Wang et al., 2024). Researchers are encouraged to leverage validated resources and updated protocols to maximize experimental rigor and translational impact.